A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5- fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck

Cancer

Volumn 85, Issue 4, 1999, Pages 952-959

  Caponigro, Francesco ^a   Comella, Pasquale ^a   Marcolin, Paolo ^a   Spena, Francesco Russo ^a   Biglietto, Maria ^b   Cartenì, Giacomo ^b   De Lucia, Luigi ^c   Avallone, Antonio ^a   Gravina, Adriano ^a   Comella, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

^c Azienda Ospedaliera di Caserta   (Italy)

Author keywords

5 fluorouracil; Cisplatin; Folinic acid; Head and neck carcinoma; Methotrexate

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; SEROTONIN 3 ANTAGONIST;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEAD AND NECK CARCINOMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; NEPHROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; ANTIDOTES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; LEUCOVORIN; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL ANALYSIS;

EID: 0033558006     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990215)85:4<952::AID-CNCR25>3.0.CO;2-N     Document Type: Article

References (38)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993;54:594-606.
2. Merlano M, Corvò R, Margarino G, Benasso M, Rosso R, Sertoli MR. Combined chemotherapy and radiation therapy in advanced inoperable squamous cell carcinoma of the head and neck. The final report of a randomized trial. Cancer 1991;67:915-21.
3. Merlano M, Vitale V, Russo R, Benasso M, Corvò R, Cavallari M, et al. Treatment of advanced squamous cell carcinoma of the head and neck with alternated chemotherapy and radiotherapy. N Engl J Med 1992;327:1115-21.
4. Merlano M, Benasso M, Corvò R, Rosso R, Vitale V, Blengio F, et al. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 1996;88: 583-9.
5. Paccagnella A, Orlando A, Marchiori C, Zorat PL, Lavariglia G, Sileni VC, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio Sui Tumori della Testa E Del Collo. J Natl Cancer Inst 1994;86:265-72.
6. Department of Veteran's Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with laryngeal cancer. N Engl J Med 1991;324:1685-90.
7. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Colletta L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst 1996;88:890-9.
8. Spaulding MB, Fisher SG, Wolf GT, Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group. Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. J Clin Oncol 1994;12:1592-9.
9. Toohill RJ, Anderson T, Byhardt RW. Cisplatin and fluorouracil as neoadjuvant therapy in head and neck cancer. Arch Otolaryngol Head Neck Surg 1987;113:758-61.
10. Martin M, Hazan A, Vergnes I, Peytral C, Mazeron JJ, Sanechaut JP, et al. Randomized study of 5-fluorouracil and cisplatin as neoadjuvant therapy in head and neck cancer: a preliminary report. Int J Radiat Oncol Biol Phys 1990;19: 973-5.
11. Thyss A, Schneider M, Santini J. Induction chemotherapy with cisplatinum and 5-fluorouracil for squamous cell carcinoma of the head and neck. Br J Cancer 1986;54:755-60.
12. Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H, et al. A phase III randomized study comparing cisplatin and 5-fluorouracil as single agent and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992:10:257-63.
13. Gebbia V, Testa A, Valenza R, Zerillo G, Restivo S, Cupido G, et al. A phase II study of levofolinic acid and fluorouracil plus cisplatin in patients with advanced head and neck carcinoma. Oncology 1993;50:490-4.
14. Schneider M, Demard F, Chauvel P. Induction chemotherapy with cisplatinum and continuous infusion 5-FU for the treatment of head and neck cancer. Six year experience at the Nice Cancer Center. Banzet P, Holland JF, Khayat D, editors. Neoadjuvant chemotherapy, Third International Congress. Paris: Springer-Verlag, 1991:18-23.
15. Arbuck SG. Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer 1989;63:1036-9.
16. Vokes EE, Schilsky RL, Weichselbaum RR. Induction chemotherapy with cisplatin, fluorouracil and high-dose leucovorin for locally advanced head and neck cancer. J Clin Oncol 1990;8:241-7.
17. Bertino JR, Mosher MB, De Conti RC. Chemotherapy of cancer of the head and neck. Cancer 1973;31:1141-9.
18. Dimery IW, Hong WK. Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 1993;85: 95-111.
19. Scanlon KJ, Newman EM, Lu Y. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 1986;83: 8923-6.
20. Caponigro F, Comella P, Daponte A, Gravina A, Cartenì G, Biglietto M, et al. A phase I study of cisplatin, methotrexate, levofolinic acid and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck. Oncol Rep 1997;4: 1207-11.
21. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53: 457-81.
22. Forastiere M, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992;10:1245-51.
23. Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PHM, Schornagel JH, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 1994;5:521-6.
24. Rooney M; Kish J, Jacobs J, Kinzie J, Weaver A, Crissman J, et al. Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120 hour 5-FU infusion and cisplatin. Cancer 1985;55:1123-8.
25. Planting AST, de Mulder PHM, de Graeff A, Verweij J. Phase II study of weekly high dose cisplatin for six weeks in patients with locally advanced squamous cell carcinoma of the head and neck. Eur J Cancer 1997;33:61-5.
26. Haines I, Bosi G, Pfister D, Spiro r, Gerald F, Sessious R, et al. Very high dose cisplatin with bleomycin infusion as initial treatment of advanced head and neck cancer. J Clin Oncol 1987;5:1594-600.
27. Ensley J, Kish J, Tapazoglou E. An intensive five course alternating combination chemotherapy induction regimen used in patients with advanced, unresectable head and neck cancer. J Clin Oncol 1988;6:1147-53.
28. Kish JA, Ensley JF, Jacobs JR. Evaluation of high dose cisplatin and 5-FU infusion as initial therapy in advanced head and neck cancer. Am J Clin Oncol 1988;11:553-7.
29. Vokes EE, Choi KE, Schilsky RL. Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer. J Clin Oncol 1988;6:618-26.
30. Vokes EE, Moran WJ, Mick R. Neoadjuvant and adjuvant methotrexate, cisplatin, and fluorouracil in multimodal therapy of head and neck cancer. J Clin Oncol 1989;7:838-45.
31. Vokes EE, Kies M, Haraf DJ, Mick R, Moran WJ, Korloff H, et al. Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: impact on the natural history of the disease. J Clin Oncol 1995;13: 876-83.
32. Vokes EE, Weichselbaum RR, Mick R, Mc Evilly JM, Haraf DJ, Panje WR. Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, leucovorin, and concomitant chemo-radiotherapy for locally advanced head and neck cancer. J Natl Cancer Inst 1992;84:877-82.
33. Schneider M, Etienne MC, Milano G, Thyss A, Otto J, Dassonville O, et al. Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. J Clin Oncol 1995;13: 1656-62.
34. Clark JR, Busse PM, Norris CM, Andersen JW, Dreyfuss AI, Rossi RM, et al. Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for squamous cell carcinoma of the head and neck: long-term results. J Clin Oncol 1997:15:3100-10.
35. Comelia P, Palmieri G, Beneduce G, Casaretti R, Daponte A, Gravina A, et al. Significance of methotrexate serum level achieved in patients with gastrointestinal malignancies treated with sequential methotrexate, I-folinic acid and 5-fluorouracil. Oncology 1996;53:198-203.
36. Comella P, Palmieri G, Lorusso V, Catalano G, Nicolella D, Ianniello GP, et al. Double biochemical modulation of 5-fluorouracil by methotrexate and levo-folinic acid in the treatment of advanced digestive tract malignancies. Eur J Cancer 1996;32:1719-26.
37. Marsh JC, Bertino JR, Katz KH, Davis CA, Durivage HJ, Rone LS, et al. The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. J Clin Oncol 1991;9:371-80.
38. Million RR, Cassissi NJ. Management of head and neck cancer: a multidisciplinary approach. Philadelphia: Lippincott, 1994:913.